Aft Pharmaceuticals Ltd. · NZX:AFT
Aft Pharmaceuticals — H1 FY2019 Earnings Presentation
12 slides from Aft Pharmaceuticals's earnings presentation, November 2018
Slide 1: AFT Pharmaceuticals Investor Presentation: H1 FY2019
AFT PHARMACEUTICALS Investor Presentation: H1 FY2019 November 2018
Slide 2: Important Notice
IMPORTANT NOTICE This presentation has been prepared by AFT Pharmaceuticals Limited (“AFT”), to provide a general overview of AFT. It is not prepared for any other purpose and must not be provided to any person other than the intended recipient. All amounts are disclosed in New Zealand dollars (NZ$)
Slide 3: H1 FY2019 Highlights
H1 FY2019 HIGHLIGHTS 128 countries that Maxigesic is licensed in – up from 125 at the end of FY2018 15 countries that Maxigesic is launched and sold in 5 number of clinical studies AFT have running in FY2019 $40.2m total income for H1 FY2019* $7.4m available cash as at 30 September 2018 – up from $6
Slide 4: Maxigesic Global Update
Italy – successful launch and MAXIGESIC GLOBAL UPDATE Nordics – launch pending 4Q FY19 sales growing still BE/LX & FR– launches pending 4Q18 Germany – licensing Eastern Europe and Balkans – NL – licensing discussions negotiations underway launches pending FY19 UK – launched underway Licensing discus
Slide 5: Maxigesic Highlights
MAXIGESIC HIGHLIGHTS Additional out-licensing and distribution agreements for Maxigesic oral dose forms have been secured to increase the number of countries to 128. Numerous Maxigesic registrations underway which are required before many launches can occur EU registrations confirmed in 25 countries
Slide 6: NasoSURF Nebuliser: Future growth strategy
NASOSURF NEBULISER: Future growth strategy A handheld ultrasonic nasal mesh nebuliser for the Product intranasal delivery of medication and treatment of description The NasoSURF Nebuliser has desirable features chronic sinusitis over currently marketed nebulisers, which are not approved for delivery
Slide 7: Revenue by Region and Channel
REVENUE BY REGION AND CHANNEL Operating revenue by region, H1 FY2019 versus H1 FY2018 NZ$000's Half Year to 30 September H1 FY2019 % of total H1 FY2018 % of total Australia 21,601 56.8% 20,206 55.3% YoY growth 7% New Zealand 12,565 33.0% 14,113 38.6% YoY growth -11% Rest of World 2,760 7.3% 1,624 4.
Slide 8: Revenue Growth
REVENUE GROWTH Operating revenue by region, H1 FY2019 – H1 FY2018 H1 FY2018 FY2018 Annual H1 FY2019 22.5 22.5 45.0 15.0 15.0 $m 30.0 $m $m 7.5 7.5 15.0 7% -11% 70% 81% - - - Au s tra lia Ne w Ze a la nd Re s t o f Wo rld S o uth e a s t As ia 4.4% 1.6% 3.1% 2.9% 7.3% 1.7% 33.8% 38.6% 55.3% 33.0% 61.
Slide 9: Summary P&L
SUMMARY P&L NZ$'000's Half Year to 30 September H1 FY2019 % of H1 FY2018 % of revenue revenue Revenue 38,045 36,561 Cost of Sales (20,292) 53.3% (22,256) 60.9% Gross Profit 17,753 46.7% 14,305 39.1% Other Income 2,430 6.4% 1,014 2.8% Selling and distribution expenses (14,234) 37.4% (12,771) 34.9% Ge
Slide 10: Summary Balance Sheet
SUMMARY BALANCE SHEET Unaudited Audited Unaudited NZ$'000's 30 Sept '19 31 March '18 30 Sept '18 ASSETS Current Assets Inventories 27,815 24,412 23,697 Trade and other receivables 12,993 16,954 14,954 Cash and cash equivalents 7,400 6,770 7,197 Derivative assets 481 176 127 Total current assets 48,6
Slide 11: Summary Cashflow Statement
SUMMARY CASHFLOW STATEMENT NZ$'000's Half Year to 30 September H1 FY2018 H1 FY2017 Net cash used in operating activities (4,339) (7,678) Net cash used in investing activities (2,821) (2,144) Net cash generated from financing activities 7,417 745 Net increase in cash 257 (9,077) Impact of foreign exc
Slide 12: Summary of Near Term Plans
SUMMARY OF NEAR TERM PLANS Drive Increased International Sales Phased launches of Maxigesic in additional countries including larger EU territories and North America Drive Increased Upfront Payments Further licensing agreements for Maxigesic and Maxigesic IV in larger markets including North America
AFT Pharmaceuticals — H1 FY2019 Earnings Presentation on 6ix